Chia Tai Enterprises International Limited

Chia Tai Enterprises International Limited engages in the manufacture and sale of chlortetracycline (CTC) and other related products in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments, Biochemical and Industrial. The Biochemical segment manufactures and sells CTC premix and CTC hydrochloride products, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance feed efficiency under the Shihao and Citifac brands. The Industrial segment engages in the sale, leasing, and servicing of caterpillar machinery equipment, including excavators, power generators, bulldozers, and compactors, as well as spare parts; and manufacture and sale of carburetors and automotive parts for automobile and motorcycle manufacturers. The company was incorporated in 1987 and is based in Central, Hong Kong. Chia Tai Enterprises International Limited is a subsidiary of Charoen Pokphand Foods Public Company Limited.

Chia Tai Enterprises International Limited trades as CAIHF on OTC. The company is classified in Consumer Defensive / Agricultural Farm Products and reports in USD.

The current profile places the business in Agricultural Farm Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $536.71M of revenue and $32.10M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Chia Tai Enterprises International Limited can be compared against peers such as Biocure Technology Inc., Biora Therapeutics, Inc., Biomind Labs Inc., Enzolytics Inc., Evofem Biosciences, Inc., Halberd Corporation.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $217.44M, beta of 3.99, and return on equity of +11.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

CAIHF currently shows total debt of $47.55M and beta of 3.99. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.ctei.com.hk

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.